© 1996 by Oxford University Press
Journal of the National Cancer Institute, Vol. 88, No. 7, 419-429,
April 3, 1996
© 1996 Oxford University Press
Antitumor Effect of c-myc Antisense Phosphorothioate Oligodeoxynucleotides on Human Melanoma Cells In Vitro and in Mice
Experimental Chemotherapy Laboratory, Regina Elena Cancer Institute Rome, Italy
Institute of Biomedical Technology Rome
Lynx Therapeutics Inc. Hayward, CA
Thomas Jefferson University, Jefferson Cancer Institute Philadelphia, PA
Correspondence to: Bruno Calabretta, M.D., Department of Microbiology and Immunology, Jefferson Cancer Institute, Thomas Jefferson University, Bluemle Life Sciences Bldg., Rm. 630, 233 S. 10th St., Philadelphia, PA 19107. or Gabriella Zupi, Ph.D., Chemioterapia Sperimentale, Istituto Regina Elena, Via Delle Messi d'Oro 158, 00161 Rome, Italy.
BACKGROUND: Phosphorothioate oligodeoxynucleotides ([S]ODNs) contain a modified internucleoside phosphate backbone. Antisense [S] ODNs targeted to specific oncogenes have been used with some therapeutic success in animal models of human leukemia; however, the potential for antisense [S]ODN treatment of solid tumors has only recently been explored.
PURPOSE: We evaluated the effects of antisense [S]ODNs targeted to the c-myc oncogene on the proliferation of human melanoma cells in vitro and on the growth of human melanoma xenografts in CD-1 nude (nu/nu) mice.
METHODS: The effects of 15-mer [S]ODNs containing c-mycsense, c-myc antisense, and two different scrambled sequences on the proliferation and viability of cultures of three established human melanoma cell lines (M14, JR8, and PLF2) were determined by measuring cell numbers and use of the trypan blue exclusion test. The induction of apoptosis in these cells following treatment with [S]ODNs was evaluated by fluorescence-activated cell sorter (FACS) analysis. FACS analysis was also used to determine the effects of [S]ODN treatment on the proliferation of primary cultures of a human melanoma explant (NG cells). The expression of cMyc protein in cultured NG cells after treatment with [S]ODNs was examined by western blot analysis. The antitumor activity and the toxic effects of several [S]ODN treatment regimens were monitored by measuring differences in tumor weight (percent tumor weight inhibition), tumor growth rate (tumor growth inhibition), animal lifespan (percent increase in lifespan), the number of toxic deaths, and the median number of lung metastases in treated and control mice bearing NG xenografts. c-Myc protein expression in NG tumor cells following [S]ODN treatment was evaluated by FACS analysis, and the extent of apoptosis in these cells was determined by FACS analysis and morphologic examination.
RESULTS: Treatment with antisense [S]ODNs, but not the others, inhibited the growth of all tested melanoma cultures in vitro; FACS analysis revealed that growth inhibition was associated with the induction of apoptosis. Antisense [S]ODN treatment also led to reduced cellular levels of c-Myc protein. In vivo, [S]ODN antitumor activity and toxicity were dose and schedule dependent; however, only antisense [S]ODNs exhibited antitumor activity. Mice bearing NG xenografts treated with antisense [S]ODNs showed a marked inhibition of tumor growth, a reduction in the number of lung metastases, and an increase in lifespan. Reduced levels of c-Myc protein and increased levels of apoptosis were also observed in NG tumor cells following antisense [S]ODN treatment.
CONCLUSIONS: Treatment of human melanoma cells and solid tumors with antisense [S]ODNs targeted to c-myc inhibits their growth and is associated with the induction of apoptosis. [J Natl Cancer Inst 1996;88:419–29]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. Leonetti, M. Scarsella, G. Riggio, A. Rizzo, E. Salvati, M. D'Incalci, L. Staszewsky, R. Frapolli, M. F. Stevens, A. Stoppacciaro, et al. G-Quadruplex Ligand RHPS4 Potentiates the Antitumor Activity of Camptothecins in Preclinical Models of Solid Tumors Clin. Cancer Res., November 15, 2008; 14(22): 7284 - 7291. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Wang, D. I. Hammoudeh, A. V. Follis, B. E. Reese, J. S. Lazo, S. J. Metallo, and E. V. Prochownik Improved low molecular weight Myc-Max inhibitors Mol. Cancer Ther., September 1, 2007; 6(9): 2399 - 2408. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Bucci, I. D'Agnano, D. Amendola, A. Citti, G. H. Raza, R. Miceli, U. De Paula, R. Marchese, S. Albini, A. Felsani, et al. Myc Down-Regulation Sensitizes Melanoma Cells to Radiotherapy by Inhibiting MLH1 and MSH2 Mismatch Repair Proteins Clin. Cancer Res., April 1, 2005; 11(7): 2756 - 2767. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Zupi, M. Scarsella, S. C. Semple, M. Mottolese, P. G. Natali, and C. Leonetti Antitumor Efficacy of bcl-2 and c-myc Antisense Oligonucleotides in Combination with Cisplatin in Human Melanoma Xenografts: Relevance of the Administration Sequence Clin. Cancer Res., March 1, 2005; 11(5): 1990 - 1998. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P N Tulley, M Neale, D Jackson, J S Chana, R Grover, I Cree, A O Grobbelaar, and G D Wilson The relation between c-myc expression and interferon sensitivity in uveal melanoma Br J Ophthalmol, December 1, 2004; 88(12): 1563 - 1567. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. M. Carbone, E. McGuffie, S. Napoli, C. E. Flanagan, C. Dembech, U. Negri, F. Arcamone, M. L. Capobianco, and C. V. Catapano DNA binding and antigene activity of a daunomycin-conjugated triplex-forming oligonucleotide targeting the P2 promoter of the human c-myc gene Nucleic Acids Res., April 30, 2004; 32(8): 2396 - 2410. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Pastorino, C. Brignole, D. Marimpietri, G. Pagnan, A. Morando, D. Ribatti, S. C. Semple, C. Gambini, T. M. Allen, and M. Ponzoni Targeted Liposomal c-myc Antisense Oligodeoxynucleotides Induce Apoptosis and Inhibit Tumor Growth and Metastases in Human Melanoma Models Clin. Cancer Res., October 1, 2003; 9(12): 4595 - 4605. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Biroccio, S. Amodei, A. Antonelli, B. Benassi, and G. Zupi Inhibition of c-Myc Oncoprotein Limits the Growth of Human Melanoma Cells by Inducing Cellular Crisis J. Biol. Chem., September 12, 2003; 278(37): 35693 - 35701. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-Y. Ryu, K. K. Mann, J. J. Schlezinger, B. Jensen, and D. H. Sherr Environmental Chemical-Induced Pro/Pre-B Cell Apoptosis: Analysis of c-Myc, p27Kip1, and p21WAF1 Reveals a Death Pathway Distinct from Clonal Deletion J. Immunol., May 15, 2003; 170(10): 4897 - 4904. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Stewart, R. C. Donehower, E. A. Eisenhauer, N. Wainman, A. K. Shah, C. Bonfils, A. R. MacLeod, J. M. Besterman, and G. K. Reid A phase I pharmacokinetic and pharmacodynamic study of the DNA methyltransferase 1 inhibitor MG98 administered twice weekly Ann. Onc., May 1, 2003; 14(5): 766 - 774. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Biroccio, B. Benassi, G. Filomeni, S. Amodei, S. Marchini, G. Chiorino, G. Rotilio, G. Zupi, and M. R. Ciriolo Glutathione Influences c-Myc-induced Apoptosis in M14 Human Melanoma Cells J. Biol. Chem., November 8, 2002; 277(46): 43763 - 43770. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Stewart, X. Xu, S. D. Thomas, and D. M. Miller Acridine-modified, clamp-forming antisense oligonucleotides synergize with cisplatin to inhibit c-Myc expression and B16-F0 tumor progression Nucleic Acids Res., June 1, 2002; 30(11): 2565 - 2574. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Mui, S. G. Raney, S. C. Semple, and M. J. Hope Immune Stimulation by a CpG-Containing Oligodeoxynucleotide Is Enhanced When Encapsulated and Delivered in Lipid Particles J. Pharmacol. Exp. Ther., September 1, 2001; 298(3): 1185 - 1192. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. W. Berg, M. Werner, P. J. Ferguson, C. Postenka, M. Vincent, D. J. Koropatnick, and E. Behrend Tumor Growth Inhibition in Vivo and G2/M Cell Cycle Arrest Induced by Antisense Oligodeoxynucleotide Targeting Thymidylate Synthase J. Pharmacol. Exp. Ther., August 1, 2001; 298(2): 477 - 484. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Biroccio, B. Benassi, S. Amodei, C. Gabellini, D. Del Bufalo, and G. Zupi C-Myc Down-Regulation Increases Susceptibility to Cisplatin through Reactive Oxygen Species-Mediated Apoptosis in M14 Human Melanoma Cells Mol. Pharmacol., July 1, 2001; 60(1): 174 - 182. [Abstract] [Full Text]
|
|
|
|
 |
|
 E. M. McGuffie, D. Pacheco, G. M. R. Carbone, and C. V. Catapano Antigene and Antiproliferative Effects of a c-myc-targeting Phosphorothioate Triple Helix-forming Oligonucleotide in Human Leukemia Cells Cancer Res., July 1, 2000; 60(14): 3790 - 3799. [Abstract] [Full Text]
|
|
|
|
|
|
C. M. Coulis, C. Lee, V. Nardone, and R. D. Prokipcak Inhibition of c-myc Expression in Cells by Targeting an RNA-Protein Interaction Using Antisense Oligonucleotides Mol. Pharmacol., March 1, 2000; 57(3): 485 - 494. [Abstract] [Full Text]
|
|
|
|
|
|
Y. Gutiérrez-Puente, A. M. Tari, C. Stephens, M. Rosenblum, R. T. Guerra, and G. Lopez-Berestein Safety, Pharmacokinetics, and Tissue Distribution of Liposomal P-Ethoxy Antisense Oligonucleotides Targeted to Bcl-2 J. Pharmacol. Exp. Ther., November 1, 1999; 291(2): 865 - 869. [Abstract] [Full Text]
|
|
|
|
|
|
C. Leonetti, A. Biroccio, A. Candiloro, G. Citro, C. Fornari, M. Mottolese, D. D. Bufalo, and G. Zupi Increase of Cisplatin Sensitivity by c-myc Antisense Oligodeoxynucleotides in a Human Metastatic Melanoma Inherently Resistant to Cisplatin Clin. Cancer Res., September 1, 1999; 5(9): 2588 - 2595. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Aziz, H. Cherwinski, and M. McMahon Complementation of Defective Colony-Stimulating Factor 1 Receptor Signaling and Mitogenesis by Raf and v-Src Mol. Cell. Biol., February 1, 1999; 19(2): 1101 - 1115. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Frederick, P. R. Holton, M. Hudson, M. Wang, and G. L. Clayman Expression of Apoptosis-related Genes in Human Head and Neck Squamous Cell Carcinomas Undergoing p53-mediated Programmed Cell Death Clin. Cancer Res., February 1, 1999; 5(2): 361 - 369. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. K. Monteith and A. A. Levin Synthetic Oligonucleotides: The Development of Antisense Therapeutics Toxicol Pathol, January 1, 1999; 27(1): 8 - 13. [Abstract] [PDF]
|
|
|
|
 |
|
 G. Tortora, R. Caputo, V. Damiano, R. Bianco, S. Pepe, A. R. Bianco, Z. Jiang, S. Agrawal, and F. Ciardiello Synergistic inhibition of human cancer cell growth by cytotoxic drugs and mixed backbone antisense oligonucleotide targeting protein kinase A PNAS, November 11, 1997; 94(23): 12586 - 12591. [Abstract] [Full Text] [PDF]
|
|